nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—Hydrocortisone—psoriasis	0.367	1	CrCtD
Norethindrone—PGR—Betamethasone—psoriasis	0.0339	0.12	CbGbCtD
Norethindrone—SHBG—Hydrocortisone—psoriasis	0.0304	0.108	CbGbCtD
Norethindrone—Fluoxymesterone—Clobetasol propionate—psoriasis	0.0253	0.0911	CrCrCtD
Norethindrone—PGR—Dexamethasone—psoriasis	0.0197	0.0698	CbGbCtD
Norethindrone—ALB—Acitretin—psoriasis	0.0192	0.0679	CbGbCtD
Norethindrone—CYP3A5—Beclomethasone—psoriasis	0.0181	0.0642	CbGbCtD
Norethindrone—Formestane—Hydrocortisone—psoriasis	0.0173	0.0623	CrCrCtD
Norethindrone—Drospirenone—Hydrocortisone—psoriasis	0.0165	0.0592	CrCrCtD
Norethindrone—Levonorgestrel—Hydrocortisone—psoriasis	0.0143	0.0516	CrCrCtD
Norethindrone—Danazol—Hydrocortisone—psoriasis	0.0132	0.0476	CrCrCtD
Norethindrone—Danazol—Prednisone—psoriasis	0.0114	0.041	CrCrCtD
Norethindrone—Cortisone acetate—Hydrocortisone—psoriasis	0.0112	0.0401	CrCrCtD
Norethindrone—Fluoxymesterone—Hydrocortisone—psoriasis	0.00996	0.0358	CrCrCtD
Norethindrone—Progesterone—Hydrocortisone—psoriasis	0.0097	0.0349	CrCrCtD
Norethindrone—Testosterone Propionate—Hydrocortisone—psoriasis	0.0097	0.0349	CrCrCtD
Norethindrone—Cortisone acetate—Prednisone—psoriasis	0.00961	0.0346	CrCrCtD
Norethindrone—Methyltestosterone—Hydrocortisone—psoriasis	0.00946	0.034	CrCrCtD
Norethindrone—Cortisone acetate—Prednisolone—psoriasis	0.00938	0.0337	CrCrCtD
Norethindrone—Fluoxymesterone—Betamethasone—psoriasis	0.00925	0.0332	CrCrCtD
Norethindrone—Fluoxymesterone—Dexamethasone—psoriasis	0.00925	0.0332	CrCrCtD
Norethindrone—Fluoxymesterone—Triamcinolone—psoriasis	0.00903	0.0325	CrCrCtD
Norethindrone—ALB—Mycophenolate mofetil—psoriasis	0.00898	0.0318	CbGbCtD
Norethindrone—Testosterone—Hydrocortisone—psoriasis	0.00842	0.0303	CrCrCtD
Norethindrone—Fluoxymesterone—Prednisolone—psoriasis	0.00837	0.0301	CrCrCtD
Norethindrone—Progesterone—Prednisolone—psoriasis	0.00815	0.0293	CrCrCtD
Norethindrone—Methyltestosterone—Prednisone—psoriasis	0.00814	0.0293	CrCrCtD
Norethindrone—Methyltestosterone—Prednisolone—psoriasis	0.00795	0.0286	CrCrCtD
Norethindrone—CYP3A7—Hydrocortisone—psoriasis	0.00772	0.0273	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00772	0.0273	CbGbCtD
Norethindrone—Hydrocortisone—Betamethasone—psoriasis	0.00735	0.0264	CrCrCtD
Norethindrone—Hydrocortisone—Dexamethasone—psoriasis	0.00735	0.0264	CrCrCtD
Norethindrone—CYP3A7—Cyclosporine—psoriasis	0.0073	0.0258	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0073	0.0258	CbGbCtD
Norethindrone—CYP3A5—Mycophenolate mofetil—psoriasis	0.00722	0.0256	CbGbCtD
Norethindrone—ALB—Prednisone—psoriasis	0.00718	0.0254	CbGbCtD
Norethindrone—Hydrocortisone—Triamcinolone—psoriasis	0.00718	0.0258	CrCrCtD
Norethindrone—Testosterone—Prednisolone—psoriasis	0.00708	0.0254	CrCrCtD
Norethindrone—Hydrocortisone—Prednisone—psoriasis	0.00681	0.0245	CrCrCtD
Norethindrone—CYP2C19—Cholecalciferol—psoriasis	0.00672	0.0238	CbGbCtD
Norethindrone—Hydrocortisone—Prednisolone—psoriasis	0.00665	0.0239	CrCrCtD
Norethindrone—CYP3A4—Calcitriol—psoriasis	0.0063	0.0223	CbGbCtD
Norethindrone—CYP3A5—Hydrocortisone—psoriasis	0.00579	0.0205	CbGbCtD
Norethindrone—CYP3A5—Cyclosporine—psoriasis	0.00547	0.0194	CbGbCtD
Norethindrone—CYP3A4—Methoxsalen—psoriasis	0.0049	0.0174	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0048	0.017	CbGbCtD
Norethindrone—CYP3A7—Dexamethasone—psoriasis	0.0048	0.017	CbGbCtD
Norethindrone—ABCB1—Mycophenolate mofetil—psoriasis	0.0047	0.0166	CbGbCtD
Norethindrone—CYP2C19—Prednisone—psoriasis	0.00466	0.0165	CbGbCtD
Norethindrone—CYP2C19—Cyclosporine—psoriasis	0.00441	0.0156	CbGbCtD
Norethindrone—ABCB1—Betamethasone—psoriasis	0.00403	0.0143	CbGbCtD
Norethindrone—ABCB1—Prednisolone—psoriasis	0.00398	0.0141	CbGbCtD
Norethindrone—ABCB1—Hydrocortisone—psoriasis	0.00377	0.0133	CbGbCtD
Norethindrone—ABCB1—Prednisone—psoriasis	0.00376	0.0133	CbGbCtD
Norethindrone—CYP3A5—Dexamethasone—psoriasis	0.0036	0.0128	CbGbCtD
Norethindrone—ALB—Methotrexate—psoriasis	0.0036	0.0128	CbGbCtD
Norethindrone—ABCB1—Cyclosporine—psoriasis	0.00356	0.0126	CbGbCtD
Norethindrone—CYP3A4—Cholecalciferol—psoriasis	0.00325	0.0115	CbGbCtD
Norethindrone—CYP2C19—Dexamethasone—psoriasis	0.00291	0.0103	CbGbCtD
Norethindrone—CYP3A4—Triamcinolone—psoriasis	0.00282	0.00997	CbGbCtD
Norethindrone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00282	0.00997	CbGbCtD
Norethindrone—CYP3A4—Betamethasone—psoriasis	0.00242	0.00855	CbGbCtD
Norethindrone—CYP3A4—Prednisolone—psoriasis	0.00238	0.00844	CbGbCtD
Norethindrone—ABCB1—Dexamethasone—psoriasis	0.00235	0.0083	CbGbCtD
Norethindrone—CYP3A4—Hydrocortisone—psoriasis	0.00226	0.008	CbGbCtD
Norethindrone—CYP3A4—Prednisone—psoriasis	0.00225	0.00797	CbGbCtD
Norethindrone—CYP3A4—Cyclosporine—psoriasis	0.00213	0.00755	CbGbCtD
Norethindrone—ABCB1—Methotrexate—psoriasis	0.00188	0.00667	CbGbCtD
Norethindrone—CYP3A4—Dexamethasone—psoriasis	0.00141	0.00497	CbGbCtD
Norethindrone—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.000178	0.0694	CbGpPWpGaD
Norethindrone—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000161	0.0626	CbGpPWpGaD
Norethindrone—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000129	0.0502	CbGpPWpGaD
Norethindrone—CYP2C19—Xenobiotics—CYP2S1—psoriasis	9.96e-05	0.0388	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL22—psoriasis	7.8e-05	0.0304	CbGpPWpGaD
Norethindrone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	7.4e-05	0.0288	CbGpPWpGaD
Norethindrone—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	7.3e-05	0.0285	CbGpPWpGaD
Norethindrone—Alopecia—Mycophenolate mofetil—psoriasis	7.04e-05	0.001	CcSEcCtD
Norethindrone—Flatulence—Cyclosporine—psoriasis	7e-05	0.000999	CcSEcCtD
Norethindrone—Mental disorder—Mycophenolate mofetil—psoriasis	6.98e-05	0.000995	CcSEcCtD
Norethindrone—Tension—Cyclosporine—psoriasis	6.97e-05	0.000994	CcSEcCtD
Norethindrone—Skin disorder—Mycophenolic acid—psoriasis	6.96e-05	0.000993	CcSEcCtD
Norethindrone—Vomiting—Acitretin—psoriasis	6.93e-05	0.000989	CcSEcCtD
Norethindrone—Vomiting—Fluocinolone Acetonide—psoriasis	6.91e-05	0.000986	CcSEcCtD
Norethindrone—Nervousness—Cyclosporine—psoriasis	6.9e-05	0.000984	CcSEcCtD
Norethindrone—Rash—Acitretin—psoriasis	6.87e-05	0.00098	CcSEcCtD
Norethindrone—Dermatitis—Acitretin—psoriasis	6.87e-05	0.000979	CcSEcCtD
Norethindrone—Haemoglobin—Triamcinolone—psoriasis	6.87e-05	0.000979	CcSEcCtD
Norethindrone—Rash—Fluocinolone Acetonide—psoriasis	6.85e-05	0.000978	CcSEcCtD
Norethindrone—Dermatitis—Fluocinolone Acetonide—psoriasis	6.85e-05	0.000977	CcSEcCtD
Norethindrone—Haemorrhage—Triamcinolone—psoriasis	6.83e-05	0.000974	CcSEcCtD
Norethindrone—Flatulence—Mycophenolate mofetil—psoriasis	6.83e-05	0.000974	CcSEcCtD
Norethindrone—Headache—Acitretin—psoriasis	6.83e-05	0.000974	CcSEcCtD
Norethindrone—Headache—Fluocinolone Acetonide—psoriasis	6.81e-05	0.000971	CcSEcCtD
Norethindrone—Acute coronary syndrome—Betamethasone—psoriasis	6.81e-05	0.000971	CcSEcCtD
Norethindrone—Acute coronary syndrome—Dexamethasone—psoriasis	6.81e-05	0.000971	CcSEcCtD
Norethindrone—Tension—Mycophenolate mofetil—psoriasis	6.8e-05	0.00097	CcSEcCtD
Norethindrone—Abdominal distension—Prednisone—psoriasis	6.79e-05	0.000968	CcSEcCtD
Norethindrone—Myocardial infarction—Dexamethasone—psoriasis	6.77e-05	0.000965	CcSEcCtD
Norethindrone—Myocardial infarction—Betamethasone—psoriasis	6.77e-05	0.000965	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Methotrexate—psoriasis	6.74e-05	0.000961	CcSEcCtD
Norethindrone—Nervousness—Mycophenolate mofetil—psoriasis	6.73e-05	0.00096	CcSEcCtD
Norethindrone—Immune system disorder—Hydrocortisone—psoriasis	6.55e-05	0.000935	CcSEcCtD
Norethindrone—Insomnia—Mycophenolic acid—psoriasis	6.48e-05	0.000925	CcSEcCtD
Norethindrone—Nausea—Acitretin—psoriasis	6.48e-05	0.000924	CcSEcCtD
Norethindrone—Nausea—Fluocinolone Acetonide—psoriasis	6.46e-05	0.000921	CcSEcCtD
Norethindrone—Somnolence—Mycophenolic acid—psoriasis	6.37e-05	0.000909	CcSEcCtD
Norethindrone—Mental disorder—Hydrocortisone—psoriasis	6.36e-05	0.000906	CcSEcCtD
Norethindrone—Dyspepsia—Mycophenolic acid—psoriasis	6.31e-05	0.0009	CcSEcCtD
Norethindrone—Hypersensitivity—Hydroxyurea—psoriasis	6.31e-05	0.000899	CcSEcCtD
Norethindrone—PGR—Ovarian Infertility Genes—VDR—psoriasis	6.27e-05	0.0244	CbGpPWpGaD
Norethindrone—Haemoglobin—Dexamethasone—psoriasis	6.23e-05	0.000888	CcSEcCtD
Norethindrone—Haemoglobin—Betamethasone—psoriasis	6.23e-05	0.000888	CcSEcCtD
Norethindrone—Haemorrhage—Betamethasone—psoriasis	6.2e-05	0.000884	CcSEcCtD
Norethindrone—Haemorrhage—Dexamethasone—psoriasis	6.2e-05	0.000884	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Mycophenolic acid—psoriasis	6.19e-05	0.000883	CcSEcCtD
Norethindrone—Fatigue—Mycophenolic acid—psoriasis	6.18e-05	0.000881	CcSEcCtD
Norethindrone—Mood swings—Methotrexate—psoriasis	6.18e-05	0.000881	CcSEcCtD
Norethindrone—Convulsion—Cyclosporine—psoriasis	6.16e-05	0.000878	CcSEcCtD
Norethindrone—Asthenia—Hydroxyurea—psoriasis	6.14e-05	0.000876	CcSEcCtD
Norethindrone—Weight increased—Prednisone—psoriasis	6.14e-05	0.000875	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	6.01e-05	0.000857	CcSEcCtD
Norethindrone—Convulsion—Mycophenolate mofetil—psoriasis	6.01e-05	0.000857	CcSEcCtD
Norethindrone—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	6e-05	0.0234	CbGpPWpGaD
Norethindrone—Depression—Prednisone—psoriasis	6e-05	0.000855	CcSEcCtD
Norethindrone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	5.99e-05	0.0233	CbGpPWpGaD
Norethindrone—Acute coronary syndrome—Prednisone—psoriasis	5.93e-05	0.000845	CcSEcCtD
Norethindrone—Myocardial infarction—Prednisone—psoriasis	5.89e-05	0.000841	CcSEcCtD
Norethindrone—Breast disorder—Methotrexate—psoriasis	5.89e-05	0.00084	CcSEcCtD
Norethindrone—Gastrointestinal pain—Mycophenolic acid—psoriasis	5.86e-05	0.000836	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	5.86e-05	0.000836	CcSEcCtD
Norethindrone—Oedema—Cyclosporine—psoriasis	5.8e-05	0.000827	CcSEcCtD
Norethindrone—Anaphylactic shock—Cyclosporine—psoriasis	5.8e-05	0.000827	CcSEcCtD
Norethindrone—Abdominal pain—Mycophenolic acid—psoriasis	5.67e-05	0.000808	CcSEcCtD
Norethindrone—Dizziness—Hydroxyurea—psoriasis	5.66e-05	0.000807	CcSEcCtD
Norethindrone—Oedema—Mycophenolate mofetil—psoriasis	5.66e-05	0.000807	CcSEcCtD
Norethindrone—Anaphylactic shock—Mycophenolate mofetil—psoriasis	5.66e-05	0.000807	CcSEcCtD
Norethindrone—Skin disorder—Cyclosporine—psoriasis	5.63e-05	0.000803	CcSEcCtD
Norethindrone—Convulsion—Prednisolone—psoriasis	5.6e-05	0.000799	CcSEcCtD
Norethindrone—Skin disorder—Mycophenolate mofetil—psoriasis	5.5e-05	0.000784	CcSEcCtD
Norethindrone—Alopecia—Betamethasone—psoriasis	5.48e-05	0.000781	CcSEcCtD
Norethindrone—Alopecia—Dexamethasone—psoriasis	5.48e-05	0.000781	CcSEcCtD
Norethindrone—Convulsion—Hydrocortisone—psoriasis	5.47e-05	0.00078	CcSEcCtD
Norethindrone—PGR—Nuclear Receptors—VDR—psoriasis	5.46e-05	0.0213	CbGpPWpGaD
Norethindrone—Vomiting—Hydroxyurea—psoriasis	5.44e-05	0.000776	CcSEcCtD
Norethindrone—Haemoglobin—Prednisone—psoriasis	5.43e-05	0.000774	CcSEcCtD
Norethindrone—Haemorrhage—Prednisone—psoriasis	5.4e-05	0.00077	CcSEcCtD
Norethindrone—Rash—Hydroxyurea—psoriasis	5.4e-05	0.00077	CcSEcCtD
Norethindrone—Dermatitis—Hydroxyurea—psoriasis	5.39e-05	0.000769	CcSEcCtD
Norethindrone—Headache—Hydroxyurea—psoriasis	5.36e-05	0.000765	CcSEcCtD
Norethindrone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	5.35e-05	0.0208	CbGpPWpGaD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	5.34e-05	0.000762	CcSEcCtD
Norethindrone—Connective tissue disorder—Prednisone—psoriasis	5.3e-05	0.000756	CcSEcCtD
Norethindrone—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	5.28e-05	0.0206	CbGpPWpGaD
Norethindrone—Anaphylactic shock—Prednisolone—psoriasis	5.28e-05	0.000753	CcSEcCtD
Norethindrone—Oedema—Prednisolone—psoriasis	5.28e-05	0.000753	CcSEcCtD
Norethindrone—Insomnia—Cyclosporine—psoriasis	5.25e-05	0.000748	CcSEcCtD
Norethindrone—Somnolence—Cyclosporine—psoriasis	5.16e-05	0.000735	CcSEcCtD
Norethindrone—Anaphylactic shock—Hydrocortisone—psoriasis	5.15e-05	0.000735	CcSEcCtD
Norethindrone—Oedema—Hydrocortisone—psoriasis	5.15e-05	0.000735	CcSEcCtD
Norethindrone—Convulsion—Triamcinolone—psoriasis	5.15e-05	0.000735	CcSEcCtD
Norethindrone—Photosensitivity reaction—Methotrexate—psoriasis	5.14e-05	0.000734	CcSEcCtD
Norethindrone—Asthenia—Mycophenolic acid—psoriasis	5.14e-05	0.000734	CcSEcCtD
Norethindrone—Insomnia—Mycophenolate mofetil—psoriasis	5.12e-05	0.00073	CcSEcCtD
Norethindrone—Dyspepsia—Cyclosporine—psoriasis	5.1e-05	0.000728	CcSEcCtD
Norethindrone—Nausea—Hydroxyurea—psoriasis	5.08e-05	0.000725	CcSEcCtD
Norethindrone—Pruritus—Mycophenolic acid—psoriasis	5.07e-05	0.000723	CcSEcCtD
Norethindrone—Somnolence—Mycophenolate mofetil—psoriasis	5.03e-05	0.000717	CcSEcCtD
Norethindrone—Drowsiness—Methotrexate—psoriasis	5.02e-05	0.000717	CcSEcCtD
Norethindrone—Depression—Methotrexate—psoriasis	5.01e-05	0.000715	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Cyclosporine—psoriasis	5.01e-05	0.000714	CcSEcCtD
Norethindrone—Skin disorder—Hydrocortisone—psoriasis	5.01e-05	0.000714	CcSEcCtD
Norethindrone—Fatigue—Cyclosporine—psoriasis	5e-05	0.000713	CcSEcCtD
Norethindrone—Dyspepsia—Mycophenolate mofetil—psoriasis	4.98e-05	0.00071	CcSEcCtD
Norethindrone—Renal failure—Methotrexate—psoriasis	4.94e-05	0.000704	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	4.88e-05	0.000697	CcSEcCtD
Norethindrone—Immune system disorder—Prednisone—psoriasis	4.88e-05	0.000695	CcSEcCtD
Norethindrone—Oedema—Triamcinolone—psoriasis	4.85e-05	0.000692	CcSEcCtD
Norethindrone—Anaphylactic shock—Triamcinolone—psoriasis	4.85e-05	0.000692	CcSEcCtD
Norethindrone—Insomnia—Prednisolone—psoriasis	4.77e-05	0.000681	CcSEcCtD
Norethindrone—Alopecia—Prednisone—psoriasis	4.77e-05	0.00068	CcSEcCtD
Norethindrone—Hepatobiliary disease—Methotrexate—psoriasis	4.75e-05	0.000678	CcSEcCtD
Norethindrone—Gastrointestinal pain—Cyclosporine—psoriasis	4.74e-05	0.000676	CcSEcCtD
Norethindrone—Dizziness—Mycophenolic acid—psoriasis	4.74e-05	0.000676	CcSEcCtD
Norethindrone—Mental disorder—Prednisone—psoriasis	4.73e-05	0.000674	CcSEcCtD
Norethindrone—Convulsion—Dexamethasone—psoriasis	4.67e-05	0.000667	CcSEcCtD
Norethindrone—Convulsion—Betamethasone—psoriasis	4.67e-05	0.000667	CcSEcCtD
Norethindrone—Insomnia—Hydrocortisone—psoriasis	4.66e-05	0.000665	CcSEcCtD
Norethindrone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	4.63e-05	0.00066	CcSEcCtD
Norethindrone—Urticaria—Cyclosporine—psoriasis	4.61e-05	0.000657	CcSEcCtD
Norethindrone—Abdominal pain—Cyclosporine—psoriasis	4.58e-05	0.000654	CcSEcCtD
Norethindrone—Vomiting—Mycophenolic acid—psoriasis	4.56e-05	0.00065	CcSEcCtD
Norethindrone—Dyspepsia—Hydrocortisone—psoriasis	4.54e-05	0.000647	CcSEcCtD
Norethindrone—Haemoglobin—Methotrexate—psoriasis	4.53e-05	0.000647	CcSEcCtD
Norethindrone—Rash—Mycophenolic acid—psoriasis	4.52e-05	0.000645	CcSEcCtD
Norethindrone—Dermatitis—Mycophenolic acid—psoriasis	4.52e-05	0.000644	CcSEcCtD
Norethindrone—Hepatitis—Methotrexate—psoriasis	4.51e-05	0.000643	CcSEcCtD
Norethindrone—Haemorrhage—Methotrexate—psoriasis	4.51e-05	0.000643	CcSEcCtD
Norethindrone—Urticaria—Mycophenolate mofetil—psoriasis	4.49e-05	0.000641	CcSEcCtD
Norethindrone—Headache—Mycophenolic acid—psoriasis	4.49e-05	0.00064	CcSEcCtD
Norethindrone—Abdominal pain—Mycophenolate mofetil—psoriasis	4.47e-05	0.000638	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.45e-05	0.000635	CcSEcCtD
Norethindrone—Fatigue—Hydrocortisone—psoriasis	4.44e-05	0.000634	CcSEcCtD
Norethindrone—Anaphylactic shock—Betamethasone—psoriasis	4.4e-05	0.000628	CcSEcCtD
Norethindrone—Oedema—Dexamethasone—psoriasis	4.4e-05	0.000628	CcSEcCtD
Norethindrone—Oedema—Betamethasone—psoriasis	4.4e-05	0.000628	CcSEcCtD
Norethindrone—Anaphylactic shock—Dexamethasone—psoriasis	4.4e-05	0.000628	CcSEcCtD
Norethindrone—Insomnia—Triamcinolone—psoriasis	4.39e-05	0.000626	CcSEcCtD
Norethindrone—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	4.34e-05	0.0169	CbGpPWpGaD
Norethindrone—PGR—Nuclear Receptor transcription pathway—VDR—psoriasis	4.32e-05	0.0168	CbGpPWpGaD
Norethindrone—Hypersensitivity—Cyclosporine—psoriasis	4.27e-05	0.000609	CcSEcCtD
Norethindrone—Dyspepsia—Triamcinolone—psoriasis	4.27e-05	0.000609	CcSEcCtD
Norethindrone—Erythema multiforme—Methotrexate—psoriasis	4.27e-05	0.000608	CcSEcCtD
Norethindrone—Nausea—Mycophenolic acid—psoriasis	4.26e-05	0.000607	CcSEcCtD
Norethindrone—Gastrointestinal pain—Hydrocortisone—psoriasis	4.21e-05	0.000601	CcSEcCtD
Norethindrone—Urticaria—Prednisolone—psoriasis	4.19e-05	0.000598	CcSEcCtD
Norethindrone—Fatigue—Triamcinolone—psoriasis	4.18e-05	0.000597	CcSEcCtD
Norethindrone—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.17e-05	0.000594	CcSEcCtD
Norethindrone—Asthenia—Cyclosporine—psoriasis	4.16e-05	0.000593	CcSEcCtD
Norethindrone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	4.13e-05	0.0161	CbGpPWpGaD
Norethindrone—Pruritus—Cyclosporine—psoriasis	4.1e-05	0.000585	CcSEcCtD
Norethindrone—Urticaria—Hydrocortisone—psoriasis	4.09e-05	0.000584	CcSEcCtD
Norethindrone—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	4.08e-05	0.0159	CbGpPWpGaD
Norethindrone—Immune system disorder—Methotrexate—psoriasis	4.07e-05	0.000581	CcSEcCtD
Norethindrone—Abdominal pain—Hydrocortisone—psoriasis	4.07e-05	0.000581	CcSEcCtD
Norethindrone—Convulsion—Prednisone—psoriasis	4.07e-05	0.000581	CcSEcCtD
Norethindrone—Asthenia—Mycophenolate mofetil—psoriasis	4.06e-05	0.000579	CcSEcCtD
Norethindrone—Pruritus—Mycophenolate mofetil—psoriasis	4e-05	0.000571	CcSEcCtD
Norethindrone—Alopecia—Methotrexate—psoriasis	3.99e-05	0.000569	CcSEcCtD
Norethindrone—Insomnia—Betamethasone—psoriasis	3.98e-05	0.000568	CcSEcCtD
Norethindrone—Insomnia—Dexamethasone—psoriasis	3.98e-05	0.000568	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.97e-05	0.000567	CcSEcCtD
Norethindrone—Mental disorder—Methotrexate—psoriasis	3.95e-05	0.000564	CcSEcCtD
Norethindrone—Hypersensitivity—Prednisolone—psoriasis	3.89e-05	0.000555	CcSEcCtD
Norethindrone—Dyspepsia—Dexamethasone—psoriasis	3.88e-05	0.000553	CcSEcCtD
Norethindrone—Dyspepsia—Betamethasone—psoriasis	3.88e-05	0.000553	CcSEcCtD
Norethindrone—Urticaria—Triamcinolone—psoriasis	3.86e-05	0.00055	CcSEcCtD
Norethindrone—Dizziness—Cyclosporine—psoriasis	3.83e-05	0.000547	CcSEcCtD
Norethindrone—Anaphylactic shock—Prednisone—psoriasis	3.83e-05	0.000547	CcSEcCtD
Norethindrone—Oedema—Prednisone—psoriasis	3.83e-05	0.000547	CcSEcCtD
Norethindrone—PGR—Nuclear Receptors—PPARG—psoriasis	3.81e-05	0.0148	CbGpPWpGaD
Norethindrone—Gastrointestinal disorder—Betamethasone—psoriasis	3.8e-05	0.000542	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Dexamethasone—psoriasis	3.8e-05	0.000542	CcSEcCtD
Norethindrone—Hypersensitivity—Hydrocortisone—psoriasis	3.8e-05	0.000542	CcSEcCtD
Norethindrone—Fatigue—Dexamethasone—psoriasis	3.8e-05	0.000541	CcSEcCtD
Norethindrone—Fatigue—Betamethasone—psoriasis	3.8e-05	0.000541	CcSEcCtD
Norethindrone—Dizziness—Mycophenolate mofetil—psoriasis	3.74e-05	0.000534	CcSEcCtD
Norethindrone—Skin disorder—Prednisone—psoriasis	3.72e-05	0.000531	CcSEcCtD
Norethindrone—Asthenia—Hydrocortisone—psoriasis	3.7e-05	0.000527	CcSEcCtD
Norethindrone—Vomiting—Cyclosporine—psoriasis	3.69e-05	0.000526	CcSEcCtD
Norethindrone—Rash—Cyclosporine—psoriasis	3.66e-05	0.000522	CcSEcCtD
Norethindrone—Dermatitis—Cyclosporine—psoriasis	3.65e-05	0.000521	CcSEcCtD
Norethindrone—Pruritus—Hydrocortisone—psoriasis	3.65e-05	0.00052	CcSEcCtD
Norethindrone—Headache—Cyclosporine—psoriasis	3.63e-05	0.000518	CcSEcCtD
Norethindrone—Gastrointestinal pain—Dexamethasone—psoriasis	3.6e-05	0.000514	CcSEcCtD
Norethindrone—Gastrointestinal pain—Betamethasone—psoriasis	3.6e-05	0.000514	CcSEcCtD
Norethindrone—Vomiting—Mycophenolate mofetil—psoriasis	3.6e-05	0.000513	CcSEcCtD
Norethindrone—Hypersensitivity—Triamcinolone—psoriasis	3.58e-05	0.00051	CcSEcCtD
Norethindrone—Rash—Mycophenolate mofetil—psoriasis	3.57e-05	0.000509	CcSEcCtD
Norethindrone—Dermatitis—Mycophenolate mofetil—psoriasis	3.56e-05	0.000508	CcSEcCtD
Norethindrone—Headache—Mycophenolate mofetil—psoriasis	3.54e-05	0.000505	CcSEcCtD
Norethindrone—Urticaria—Betamethasone—psoriasis	3.5e-05	0.000499	CcSEcCtD
Norethindrone—Urticaria—Dexamethasone—psoriasis	3.5e-05	0.000499	CcSEcCtD
Norethindrone—Dizziness—Prednisolone—psoriasis	3.49e-05	0.000498	CcSEcCtD
Norethindrone—Asthenia—Triamcinolone—psoriasis	3.48e-05	0.000497	CcSEcCtD
Norethindrone—Abdominal pain—Betamethasone—psoriasis	3.48e-05	0.000496	CcSEcCtD
Norethindrone—Abdominal pain—Dexamethasone—psoriasis	3.48e-05	0.000496	CcSEcCtD
Norethindrone—Insomnia—Prednisone—psoriasis	3.47e-05	0.000495	CcSEcCtD
Norethindrone—Nausea—Cyclosporine—psoriasis	3.44e-05	0.000491	CcSEcCtD
Norethindrone—Pruritus—Triamcinolone—psoriasis	3.43e-05	0.00049	CcSEcCtD
Norethindrone—Dizziness—Hydrocortisone—psoriasis	3.41e-05	0.000486	CcSEcCtD
Norethindrone—Convulsion—Methotrexate—psoriasis	3.4e-05	0.000485	CcSEcCtD
Norethindrone—Dyspepsia—Prednisone—psoriasis	3.38e-05	0.000481	CcSEcCtD
Norethindrone—Nausea—Mycophenolate mofetil—psoriasis	3.36e-05	0.000479	CcSEcCtD
Norethindrone—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	3.35e-05	0.0131	CbGpPWpGaD
Norethindrone—Rash—Prednisolone—psoriasis	3.33e-05	0.000475	CcSEcCtD
Norethindrone—Dermatitis—Prednisolone—psoriasis	3.32e-05	0.000474	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.32e-05	0.000474	CcSEcCtD
Norethindrone—Fatigue—Prednisone—psoriasis	3.31e-05	0.000472	CcSEcCtD
Norethindrone—Headache—Prednisolone—psoriasis	3.31e-05	0.000472	CcSEcCtD
Norethindrone—Vomiting—Hydrocortisone—psoriasis	3.28e-05	0.000467	CcSEcCtD
Norethindrone—ALB—HDL-mediated lipid transport—APOE—psoriasis	3.26e-05	0.0127	CbGpPWpGaD
Norethindrone—Rash—Hydrocortisone—psoriasis	3.25e-05	0.000463	CcSEcCtD
Norethindrone—Dermatitis—Hydrocortisone—psoriasis	3.25e-05	0.000463	CcSEcCtD
Norethindrone—Headache—Hydrocortisone—psoriasis	3.23e-05	0.00046	CcSEcCtD
Norethindrone—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	3.23e-05	0.0126	CbGpPWpGaD
Norethindrone—Dizziness—Triamcinolone—psoriasis	3.21e-05	0.000458	CcSEcCtD
Norethindrone—Anaphylactic shock—Methotrexate—psoriasis	3.2e-05	0.000457	CcSEcCtD
Norethindrone—PGR—Validated nuclear estrogen receptor alpha network—PCNA—psoriasis	3.19e-05	0.0125	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—CYP2S1—psoriasis	3.19e-05	0.0124	CbGpPWpGaD
Norethindrone—Asthenia—Dexamethasone—psoriasis	3.16e-05	0.000451	CcSEcCtD
Norethindrone—Asthenia—Betamethasone—psoriasis	3.16e-05	0.000451	CcSEcCtD
Norethindrone—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	3.14e-05	0.0122	CbGpPWpGaD
Norethindrone—Gastrointestinal pain—Prednisone—psoriasis	3.14e-05	0.000447	CcSEcCtD
Norethindrone—Nausea—Prednisolone—psoriasis	3.13e-05	0.000447	CcSEcCtD
Norethindrone—PGR—Cellular roles of Anthrax toxin—TNF—psoriasis	3.13e-05	0.0122	CbGpPWpGaD
Norethindrone—Pruritus—Dexamethasone—psoriasis	3.12e-05	0.000444	CcSEcCtD
Norethindrone—Pruritus—Betamethasone—psoriasis	3.12e-05	0.000444	CcSEcCtD
Norethindrone—Skin disorder—Methotrexate—psoriasis	3.11e-05	0.000444	CcSEcCtD
Norethindrone—Vomiting—Triamcinolone—psoriasis	3.09e-05	0.00044	CcSEcCtD
Norethindrone—Nausea—Hydrocortisone—psoriasis	3.06e-05	0.000437	CcSEcCtD
Norethindrone—Rash—Triamcinolone—psoriasis	3.06e-05	0.000436	CcSEcCtD
Norethindrone—Dermatitis—Triamcinolone—psoriasis	3.06e-05	0.000436	CcSEcCtD
Norethindrone—Urticaria—Prednisone—psoriasis	3.05e-05	0.000434	CcSEcCtD
Norethindrone—Headache—Triamcinolone—psoriasis	3.04e-05	0.000434	CcSEcCtD
Norethindrone—Abdominal pain—Prednisone—psoriasis	3.03e-05	0.000432	CcSEcCtD
Norethindrone—PGR—Nuclear Receptor transcription pathway—PPARG—psoriasis	3.01e-05	0.0117	CbGpPWpGaD
Norethindrone—Dizziness—Dexamethasone—psoriasis	2.91e-05	0.000415	CcSEcCtD
Norethindrone—Dizziness—Betamethasone—psoriasis	2.91e-05	0.000415	CcSEcCtD
Norethindrone—Insomnia—Methotrexate—psoriasis	2.9e-05	0.000413	CcSEcCtD
Norethindrone—Nausea—Triamcinolone—psoriasis	2.88e-05	0.000411	CcSEcCtD
Norethindrone—Somnolence—Methotrexate—psoriasis	2.85e-05	0.000406	CcSEcCtD
Norethindrone—Hypersensitivity—Prednisone—psoriasis	2.83e-05	0.000403	CcSEcCtD
Norethindrone—Dyspepsia—Methotrexate—psoriasis	2.82e-05	0.000402	CcSEcCtD
Norethindrone—Vomiting—Betamethasone—psoriasis	2.8e-05	0.000399	CcSEcCtD
Norethindrone—Vomiting—Dexamethasone—psoriasis	2.8e-05	0.000399	CcSEcCtD
Norethindrone—Rash—Betamethasone—psoriasis	2.78e-05	0.000396	CcSEcCtD
Norethindrone—Rash—Dexamethasone—psoriasis	2.78e-05	0.000396	CcSEcCtD
Norethindrone—Dermatitis—Dexamethasone—psoriasis	2.77e-05	0.000396	CcSEcCtD
Norethindrone—Dermatitis—Betamethasone—psoriasis	2.77e-05	0.000396	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Methotrexate—psoriasis	2.77e-05	0.000395	CcSEcCtD
Norethindrone—Fatigue—Methotrexate—psoriasis	2.76e-05	0.000394	CcSEcCtD
Norethindrone—Headache—Betamethasone—psoriasis	2.76e-05	0.000393	CcSEcCtD
Norethindrone—Headache—Dexamethasone—psoriasis	2.76e-05	0.000393	CcSEcCtD
Norethindrone—Asthenia—Prednisone—psoriasis	2.75e-05	0.000392	CcSEcCtD
Norethindrone—Pruritus—Prednisone—psoriasis	2.71e-05	0.000387	CcSEcCtD
Norethindrone—Gastrointestinal pain—Methotrexate—psoriasis	2.62e-05	0.000374	CcSEcCtD
Norethindrone—Nausea—Betamethasone—psoriasis	2.62e-05	0.000373	CcSEcCtD
Norethindrone—Nausea—Dexamethasone—psoriasis	2.62e-05	0.000373	CcSEcCtD
Norethindrone—Urticaria—Methotrexate—psoriasis	2.55e-05	0.000363	CcSEcCtD
Norethindrone—Dizziness—Prednisone—psoriasis	2.54e-05	0.000362	CcSEcCtD
Norethindrone—Abdominal pain—Methotrexate—psoriasis	2.53e-05	0.000361	CcSEcCtD
Norethindrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	2.49e-05	0.00969	CbGpPWpGaD
Norethindrone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	2.45e-05	0.00956	CbGpPWpGaD
Norethindrone—Vomiting—Prednisone—psoriasis	2.44e-05	0.000348	CcSEcCtD
Norethindrone—Rash—Prednisone—psoriasis	2.42e-05	0.000345	CcSEcCtD
Norethindrone—Dermatitis—Prednisone—psoriasis	2.42e-05	0.000345	CcSEcCtD
Norethindrone—Headache—Prednisone—psoriasis	2.4e-05	0.000343	CcSEcCtD
Norethindrone—Hypersensitivity—Methotrexate—psoriasis	2.36e-05	0.000337	CcSEcCtD
Norethindrone—CYP3A5—Biological oxidations—CYP2S1—psoriasis	2.3e-05	0.00898	CbGpPWpGaD
Norethindrone—Asthenia—Methotrexate—psoriasis	2.3e-05	0.000328	CcSEcCtD
Norethindrone—Nausea—Prednisone—psoriasis	2.28e-05	0.000325	CcSEcCtD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	2.27e-05	0.00885	CbGpPWpGaD
Norethindrone—Pruritus—Methotrexate—psoriasis	2.27e-05	0.000323	CcSEcCtD
Norethindrone—Dizziness—Methotrexate—psoriasis	2.12e-05	0.000302	CcSEcCtD
Norethindrone—Vomiting—Methotrexate—psoriasis	2.04e-05	0.000291	CcSEcCtD
Norethindrone—Rash—Methotrexate—psoriasis	2.02e-05	0.000288	CcSEcCtD
Norethindrone—Dermatitis—Methotrexate—psoriasis	2.02e-05	0.000288	CcSEcCtD
Norethindrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	2.02e-05	0.00786	CbGpPWpGaD
Norethindrone—Headache—Methotrexate—psoriasis	2.01e-05	0.000286	CcSEcCtD
Norethindrone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	1.99e-05	0.00775	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	1.91e-05	0.00746	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—TARS—psoriasis	1.91e-05	0.00744	CbGpPWpGaD
Norethindrone—Nausea—Methotrexate—psoriasis	1.9e-05	0.000271	CcSEcCtD
Norethindrone—ALB—Lipoprotein metabolism—APOE—psoriasis	1.87e-05	0.00729	CbGpPWpGaD
Norethindrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	1.85e-05	0.00722	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—CYP2S1—psoriasis	1.78e-05	0.00694	CbGpPWpGaD
Norethindrone—PGR—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	1.78e-05	0.00694	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	1.76e-05	0.00684	CbGpPWpGaD
Norethindrone—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	1.73e-05	0.00673	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SERPINB8—psoriasis	1.53e-05	0.00595	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-C—psoriasis	1.48e-05	0.00576	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL13—psoriasis	1.47e-05	0.00572	CbGpPWpGaD
Norethindrone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	1.46e-05	0.00568	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL17A—psoriasis	1.35e-05	0.00527	CbGpPWpGaD
Norethindrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.29e-05	0.00504	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—CAT—psoriasis	1.28e-05	0.005	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL12B—psoriasis	1.26e-05	0.0049	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—CRP—psoriasis	1.25e-05	0.00488	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—CARM1—psoriasis	1.25e-05	0.00487	CbGpPWpGaD
Norethindrone—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	1.24e-05	0.00485	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-E—psoriasis	1.23e-05	0.00478	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—APOE—psoriasis	1.22e-05	0.00477	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL4—psoriasis	1.18e-05	0.00459	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	1.15e-05	0.00448	CbGpPWpGaD
Norethindrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	1.14e-05	0.00445	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—TYK2—psoriasis	1.1e-05	0.00429	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	1.07e-05	0.00417	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	1.06e-05	0.00412	CbGpPWpGaD
Norethindrone—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	1.03e-05	0.004	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—CAT—psoriasis	1.02e-05	0.00397	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—CRP—psoriasis	1.02e-05	0.00397	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	1.01e-05	0.00396	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—ICAM1—psoriasis	9.35e-06	0.00365	CbGpPWpGaD
Norethindrone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	9.24e-06	0.0036	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL10—psoriasis	9.19e-06	0.00358	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL4—psoriasis	8.94e-06	0.00348	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HCAR2—psoriasis	8.85e-06	0.00345	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	8.75e-06	0.00341	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-B—psoriasis	8.74e-06	0.00341	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	8.73e-06	0.0034	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	8.13e-06	0.00317	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-A—psoriasis	8.1e-06	0.00316	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—CRP—psoriasis	8.08e-06	0.00315	CbGpPWpGaD
Norethindrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.96e-06	0.0031	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TAGAP—psoriasis	7.67e-06	0.00299	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—VDR—psoriasis	7.45e-06	0.00291	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	7.43e-06	0.0029	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	7.4e-06	0.00288	CbGpPWpGaD
Norethindrone—ALB—SLC-mediated transmembrane transport—CP—psoriasis	7.29e-06	0.00284	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	7.28e-06	0.00284	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IFNG—psoriasis	7.12e-06	0.00277	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—NDUFA5—psoriasis	6.41e-06	0.0025	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—CARM1—psoriasis	6.01e-06	0.00234	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—NFKB1—psoriasis	5.92e-06	0.00231	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—TNF—psoriasis	5.66e-06	0.00221	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—IFNG—psoriasis	5.65e-06	0.0022	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP2S1—psoriasis	5.45e-06	0.00212	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IFNG—psoriasis	5.4e-06	0.00211	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	5.39e-06	0.0021	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—IL6—psoriasis	5.38e-06	0.0021	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—PPARG—psoriasis	5.2e-06	0.00203	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CXCL8—psoriasis	5.02e-06	0.00196	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.71e-06	0.00184	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	4.71e-06	0.00183	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NDUFA5—psoriasis	4.63e-06	0.00181	CbGpPWpGaD
Norethindrone—ALB—Platelet degranulation—VEGFA—psoriasis	4.61e-06	0.0018	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TNF—psoriasis	4.61e-06	0.0018	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCL20—psoriasis	4.6e-06	0.00179	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—IL6—psoriasis	4.57e-06	0.00178	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—ITGAL—psoriasis	4.43e-06	0.00173	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	4.39e-06	0.00171	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.14e-06	0.00161	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.08e-06	0.00159	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TP53—psoriasis	4.06e-06	0.00158	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NDUFA5—psoriasis	3.99e-06	0.00155	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP2S1—psoriasis	3.94e-06	0.00154	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.72e-06	0.00145	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL6—psoriasis	3.72e-06	0.00145	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—CP—psoriasis	3.71e-06	0.00144	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—TNF—psoriasis	3.66e-06	0.00143	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—VDR—psoriasis	3.59e-06	0.0014	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NDUFA5—psoriasis	3.58e-06	0.0014	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	3.54e-06	0.00138	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—TNF—psoriasis	3.5e-06	0.00136	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NDUFA5—psoriasis	3.49e-06	0.00136	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.48e-06	0.00135	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP2S1—psoriasis	3.39e-06	0.00132	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.34e-06	0.0013	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.25e-06	0.00127	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.1e-06	0.00121	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP2S1—psoriasis	3.04e-06	0.00119	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP2S1—psoriasis	2.97e-06	0.00116	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—IL6—psoriasis	2.95e-06	0.00115	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CARM1—psoriasis	2.66e-06	0.00104	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SOCS1—psoriasis	2.53e-06	0.000986	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—PPARG—psoriasis	2.5e-06	0.000975	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.3e-06	0.000898	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.22e-06	0.000865	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NDUFA5—psoriasis	2.15e-06	0.000839	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.04e-06	0.000797	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.01e-06	0.000785	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CARM1—psoriasis	1.92e-06	0.00075	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—LEP—psoriasis	1.87e-06	0.000728	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—APOE—psoriasis	1.87e-06	0.000728	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP2S1—psoriasis	1.83e-06	0.000714	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—NOS2—psoriasis	1.82e-06	0.000709	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.78e-06	0.000693	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—NFKBIA—psoriasis	1.74e-06	0.000678	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.73e-06	0.000672	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CARM1—psoriasis	1.66e-06	0.000646	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CAT—psoriasis	1.64e-06	0.000638	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.6e-06	0.000622	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.55e-06	0.000603	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.52e-06	0.000593	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CARM1—psoriasis	1.49e-06	0.00058	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CARM1—psoriasis	1.45e-06	0.000566	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TYK2—psoriasis	1.43e-06	0.000556	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.39e-06	0.000542	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—APOE—psoriasis	1.27e-06	0.000496	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCL8—psoriasis	1.24e-06	0.000484	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CAT—psoriasis	1.18e-06	0.000461	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—JUN—psoriasis	1.15e-06	0.00045	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—NFKB1—psoriasis	1.11e-06	0.000433	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PPARG—psoriasis	1.11e-06	0.000432	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—VEGFA—psoriasis	1.05e-06	0.000411	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CAT—psoriasis	1.02e-06	0.000397	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—VEGFA—psoriasis	1.01e-06	0.000393	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—STAT3—psoriasis	9.98e-07	0.000389	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—APOE—psoriasis	9.19e-07	0.000358	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CAT—psoriasis	9.15e-07	0.000356	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CARM1—psoriasis	8.94e-07	0.000349	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CAT—psoriasis	8.93e-07	0.000348	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PPARG—psoriasis	8.01e-07	0.000312	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TP53—psoriasis	7.96e-07	0.00031	CbGpPWpGaD
Norethindrone—ALB—Metabolism—APOE—psoriasis	7.92e-07	0.000309	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TP53—psoriasis	7.62e-07	0.000297	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—APOE—psoriasis	7.11e-07	0.000277	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL6—psoriasis	6.97e-07	0.000272	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—APOE—psoriasis	6.94e-07	0.00027	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PPARG—psoriasis	6.89e-07	0.000269	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PPARG—psoriasis	6.19e-07	0.000241	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PPARG—psoriasis	6.04e-07	0.000235	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CAT—psoriasis	5.5e-07	0.000214	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—APOE—psoriasis	4.27e-07	0.000167	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PPARG—psoriasis	3.72e-07	0.000145	CbGpPWpGaD
